AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...

More on AI: When it comes to folding AI tools into mammograms, AI firms believe there’s even more knowledge to be gleaned ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of high unmet need, ...

Dilon Technologies, a leading provider of medical devices, has gained FDA approval for its MarginProbe® 2 system and is announcing its launch in the U.S. This is the next-generation device for ...

A new generation of AI algorithms aim to go beyond detecting cancers to predicting risk for cardiovascular diseases.

Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...

The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...

There is still time to complete key health screenings before the end of the year, and Check Up 13 is making it easier than ever.

The British presenter Davina McCall has shared an update on her health following her breast cancer surgery. See details below ...

A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...

A long-awaited study shows that screening for breast cancer with annual mammograms may not always be the best way to catch ...